Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines

Cancer Treatment Reviews

Volumn 30, Issue 7, 2004, Pages 643-650

  Pouillart, Pierre ^a  

^a INSTITUT CURIE   (France)

Author keywords

Anthracycline; Cancer; Cardioprotectant; Cardiotoxicity; Chemotherapy; Congestive heart failure; Dexrazoxane; Doxorubicin; Epirubicin; Tumour

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IDARUBICIN; PACLITAXEL; PIRARUBICIN; PLACEBO; RAZOXANE; TRASTUZUMAB;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; DYSPNEA; EVALUATION; HEART ARRHYTHMIA; HEART LEFT VENTRICLE FAILURE; HEART PALPITATION; HEART PROTECTION; HEART VENTRICLE EXTRASYSTOLE; HUMAN; IRON CHELATION; LUNG EDEMA; LUNG SMALL CELL CANCER; NONHUMAN; SOFT TISSUE SARCOMA; TACHYCARDIA;

ADULT; ANIMALS; ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; CHILD; HEART FAILURE, CONGESTIVE; HUMANS; RAZOXANE;

EID: 7544243756     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2004.06.002     Document Type: Article

References (50)

1. Weiss R.B. The anthracyclines: Will we ever find a better doxorubicin Semin. Oncol. 19 1992 670-686
2. Gianni L. Munzone E. Capri G. et al. Paclitaxel by 3-h infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study J. Clin. Oncol. 13 1995 2688-2699
3. Dombernowsky P. Gehl J. Boesgaard M. Paaske T. Jensen B.V. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer Semin. Oncol. 23 1996 23-27
4. Sparano J.A. Hu P. Rao R.M. Falkson C.I. Wolff A.C. Wood W.C. Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: An Eastern Cooperative Oncology Group Study J. Clin. Oncol. 17 1999 3828-3834
5. Hensley M.L. Schuchter L.M. Lindley C. et al. American Society of clinical oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants J. Clin. Oncol. 17 1999 3333-3355
6. Hellmann K. Dexrazoxane and the ASCO guidelines for the use of chemotherapy and radiotherapy products: A critique J. Clin. Oncol. 18 2000 2004-2006
7. Lipshultz S.E. Colan S.D. Gelber R.D. Perez-Atayde A.R. Sallan S.E. Sanders S.P. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood N. Engl. J. Med. 324 1991 808-815
8. Von Hoff D.D. Layard M.W. Basa P. et al. Risk factors for doxorubicin induced congestive heart failure Ann. Intern. Med. 91 1979 710-717
9. Speyer J.L. Green M.D. Zeleniuch-Jacotte A. et al. ICRF-187 permits longer treatment with doxorubicin in women with breast cancer J. Clin. Oncol. 10 1992 117-127
10. Steinherz L.J. Steinherz P.G. Tan C.T.C. Heller G. Murphy M.L. Cardiac toxicity 4 to 20 years after completing anthracycline therapy JAMA 266 1991 1672-1677
11. Allen A. The cardiotoxicity of chemotherapeutic drugs Semin. Oncol. 19 1992 529-542
12. Lipshultz S.E. Lipsitz S.R. Mone S.M. et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer N. Engl. J. Med. 332 1995 1738-1743
13. Legha S.S. Benjamin R.S. Mackay B. et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion Ann. Intern. Med. 96 1982 133-139
14. Shapira J. Gottfried M. Lisner M. Ravid M. Reduced cardiotoxicity of doxorubicin by a 6-h infusion regimen Cancer 65 1990 870-873
15. Casper E.S. Gaynor J.J. Hadju S.I. et al. A prospective randomized trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high grade extremity soft tissue sarcoma and an analysis of prognostic factors Cancer 68 1991 1221-1229
16. Bristow M.R. Mason J.W. Billingham M.E. Daniels J.R. Dose-effect and structure function relationships in doxorubicin cardiomyopathy Am. Heart J. 102 1981 709-718
17. Lipshultz S.E. Sallan S.E. Giantris A.L. Lipsitz S.R. Dalton V. Colan S.D. 48 h continuous doxorubicin infusion is not cardioprotective in children assessed 18 months later: The DFCI 91001 ALL protocol Proc. Am. Soc. Clin. Oncol. 17 1998 2028
18. Dieras V. Barthier S. Beuzeboc P. et al. A phase II study of Taxotere (T) in combination with doxorubicin (A) as first line chemotherapy (CT) of metastatic breast cancer (MBC) Breast Cancer Res. Treat 50 1998 226
19. Johnston S.R. Gore M.E. Caelyx: Phase II studies in ovarian cancer Eur. J. Cancer 37 Suppl. 9 2001 S8-S14
20. Slamon D.J. Leyland-Jones B. Shak S. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N. Engl. J. Med. 344 2001 783-792
21. Perez E.A. Hortobagyi G.N. Ongoing and planned adjuvant trials with trastuzumab Semin. Oncol. 27 2000 26-32
22. Goram A.L. Richmond P.L. Pegylated liposomal doxorubicin: Tolerability and toxicity Pharmacotherapy 21 2001 751-763
23. Nabholtz J.M. Mackey J.R. Smylie M. et al. Final results of a Phase II study of Taxotere (T), doxorubicin (A) and cyclophosphamide (C) (TAC) as first line chemotherapy (CT) in metastatic breast cancer (MBC) patients Breast Cancer Res. Treat 50 1998 227
24. Swain SM Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: Expert panel review. Cancer Res Clin Oncol 2003 129 [in press; will be published November 2003, issue 12; page numbers to be confirmed]
25. Bristow M.R. Thompson P.D. Martin R.P. Mason J.W. Billingham M.E. Harrison D.C. Early anthracycline cardiotoxicity Am. J. Med. 65 1978 823-832
26. Herman E.H. Witiak D.T. Hellmann K. Waravdekar V.S. Biological properties of ICRF-159 and related bis (dioxopiperazine) compounds Adv. Pharmacol. Chemother. 19 1982 249-290
27. Herman E.H. Ardalan B. Bier C. Waravdekar V.S. Krop S. Reduction of daunorubicin lethality and myocardial cellular alterations by pretreatment with ICRF-187 in Syrian golden hamsters Cancer Treat Rep. 63 1979 89-92
28. Herman E.H. Ferrans V.J. Myers C.E. Van Vleet J.F. Comparison of the effectiveness of (±)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles Cancer Res. 45 1985 276-281
29. Herman E.H. Ferrans V.J. Jordan W. Ardalan B. Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits Res. Commun. Chem. Pathol. Pharmacol. 31 1981 85-97
30. Herman E.H. Ferrans V.J. Reduction of chronic doxorubicin cardiotoxicity in dogs by pretreatment with (±)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane (ICRF-187) Cancer Res. 41 1981 3436-3440
31. Herman E.H. Ferrans V.J. Influence of vitamin E and ICRF-187 on chronic doxorubicin cardiotoxicity in miniature swine Lab. Invest. 49 1983 69-77
32. Herman E.H. Ferrans V.J. Pretreatment with ICRF-187 provides long-lasting protection against chronic daunorubicin cardiotoxicity in rabbits Cancer Chemother. Pharmacol. 16 1986 102-106
33. Dardir M. Herman E.H. Ferrans V.J. Effects of ICRF-187 on the cardiac and renal toxicity of epirubicin in spontaneously hypertensive rats Cancer Chemother. Pharmacol. 23 1989 269-275
34. Herman E.H. Ferrans V.J. Young R.S.K. Hamlin R.L. Effect of pretreatment with ICRF-187 on the total cumulative dose of doxorubicin tolerated by beagle dogs Cancer Res. 48 1988 6918-6925
35. Herman E.H. El-Hage A.N. Ferrans V.J. Witiak D.T. Reduction by ICRF-187 of acute doxorubicin toxicity in Syrian golden hamsters Res. Commun. Chem. Pathol. Pharmacol. 40 1983 217-231
36. Ten Bokkel Huinink W.W. Schreuder J.E. Dubbelman R. et al. ICRF 187 protects against doxorubicin induced cardiomyopathy Ann. Oncol. 3 1992 114
37. Feldmann J.E. Jones S.E. Weisberg S.R. et al. Advanced small cell lung cancer treated with CAV (cyclophosphamide + Adriamycin ® + vincristine) chemotherapy and the cardioprotective agent dexrazoxane (ADR529, ICRF187, Zinecard ®) Proc. Am. Soc. Clin. Oncol. 11 1992 993
38. Lopez M. Vici P. Di Lauro L. et al. Randomized prospective clinical trial to evaluate cardio-protection of dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas J. Clin. Oncol. 16 1998 1-7
39. Swain S.M. Whaley F.S. Gerber M.C. et al. Cardioprotective with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer J. Clin. Oncol. 15 1997 1318-1322
40. Speyer J.L. Green M.D. Kramer E. et al. Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer New Engl. J. Med. 319 1988 745-752
41. Swain S.M. Whaley F.S. Gerber M.C. et al. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy J. Clin. Oncol. 15 1997 1333-1340
42. Venturini M. Michelotti A. Del Mastro L. et al. Multicenter randomized controlled clinical trial to evaluate cardio-protection of dexrazoxane versus no cardio-protection in women receiving epirubicin chemotherapy for advanced breast cancer J. Clin. Oncol. 14 1996 3112-3120
43. Wexler L.H. Andrich M.P. Venzon D. et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin J. Clin. Oncol. 14 1996 362-372
44. Rubio M.E. Wiegman A. Naeff M.S.J. et al. ICRF 187 (Cardioxane) protection against doxorubicin induced cardiomyopathy in paediatric osteosarcoma patients Proc. Am. Soc. Clin. Oncol. 14 1995 440
45. Bu'Lock F.A. Gabriel H.M. Oakhill A. Mott M.G. Martin R.P. Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease Br. Heart J. 70 1993 185-188
46. Schiavetti A. Castello M.A. Versacci P. et al. Use of ICRF-187 for prevention of anthracycline cardiotoxicity in children: preliminary results Pediatr. Hematol. Oncol. 14 1997 213-222
47. Chiron Therapeutics, Amsterdam, The Netherlands. A phase III randomised comparison of cardioprotection with Cardioxane (dexrazoxane, ICRF187) versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. Clinical study report EC-CX-006, 1999
48. Wadler S. Green M.D. Muggia F.M. Synergistic activity of doxorubicin and the bisdioxopiperazine (±)-1,2-bis(3,5-dioxopiperazinyl-1-yl) propane (ICRF-187) against murine sarcoma S180 cell line Cancer Res. 46 1986 1176-1181
49. Soudon J. Study of the in vitro cytotoxicity of doxorubicin combined with Cardioxane® to 9 breast cancer cell lines. French Marketing Authorization Application File
50. Verhoef V. Bell V. Filppi J. Effect of the cardioprotective agent ADR-529 (ICRF187) on the antitumor activity of doxorubicin Proc. Am. Assoc. Cancer Res. 29 1988